Corcept TherapeuticsCORT
CORT
About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Employees: 500
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
172% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 29
14% more funds holding
Funds holding: 317 [Q3] → 361 (+44) [Q4]
5% more capital invested
Capital invested by funds: $4.04B [Q3] → $4.24B (+$200M) [Q4]
3% less repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 120
3.26% less ownership
Funds ownership: 83.64% [Q3] → 80.38% (-3.26%) [Q4]
21% less call options, than puts
Call options by funds: $58.4M | Put options by funds: $73.7M
29% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 5 (-2) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$78
44%
upside
Avg. target
$108
99%
upside
High target
$130
140%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler David Amsellem 51% 1-year accuracy 18 / 35 met price target | 44%upside $78 | Overweight Maintained | 27 Feb 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 45 / 199 met price target | 112%upside $115 | Buy Reiterated | 27 Feb 2025 |
Canaccord Genuity Edward Nash 52% 1-year accuracy 11 / 21 met price target | 140%upside $130 | Buy Maintained | 30 Jan 2025 |
Financial journalist opinion
Based on 34 articles about CORT published over the past 30 days
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (CORT) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Neutral
PRNewsWire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Neutral
Accesswire
3 days ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Neutral
Business Wire
3 days ago
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the initiation of MOMENTUM, a clinical trial examining the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension. The MOMENTUM trial,.
Neutral
Accesswire
4 days ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Neutral
Accesswire
4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Positive
Zacks Investment Research
6 days ago
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.
Neutral
Accesswire
6 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Neutral
Accesswire
1 week ago
Corcept Therapeutics Incorporated (CORT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT.
Charts implemented using Lightweight Charts™